18.00
price down icon2.60%   -0.48
after-market Handel nachbörslich: 17.97 -0.03 -0.17%
loading
Schlusskurs vom Vortag:
$18.48
Offen:
$18.36
24-Stunden-Volumen:
644.77K
Relative Volume:
0.91
Marktkapitalisierung:
$1.24B
Einnahmen:
$71.30M
Nettoeinkommen (Verlust:
$-354.80M
KGV:
-3.22
EPS:
-5.59
Netto-Cashflow:
$-356.00M
1W Leistung:
-5.21%
1M Leistung:
-30.39%
6M Leistung:
-28.63%
1J Leistung:
-54.59%
1-Tages-Spanne:
Value
$17.61
$18.60
1-Wochen-Bereich:
Value
$17.37
$19.90
52-Wochen-Spanne:
Value
$17.37
$53.08

Arvinas Inc Stock (ARVN) Company Profile

Name
Firmenname
Arvinas Inc
Name
Telefon
203-535-1456
Name
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Name
Mitarbeiter
445
Name
Twitter
@ArvinasInc
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
ARVN's Discussions on Twitter

Vergleichen Sie ARVN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ARVN
Arvinas Inc
18.00 1.24B 71.30M -354.80M -356.00M -5.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
405.27 104.37B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
715.13 78.59B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
628.32 37.57B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.26 31.25B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.51 27.21B 3.30B -501.07M 1.03B -2.1146

Arvinas Inc Stock (ARVN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-10 Eingeleitet BTIG Research Buy
2024-11-18 Eingeleitet Stephens Overweight
2024-02-28 Bestätigt Oppenheimer Outperform
2024-02-14 Herabstufung Citigroup Buy → Neutral
2024-02-01 Eingeleitet Goldman Buy
2023-12-19 Hochstufung Wells Fargo Equal Weight → Overweight
2023-12-06 Hochstufung Jefferies Hold → Buy
2023-11-20 Hochstufung Guggenheim Neutral → Buy
2023-10-23 Hochstufung Wedbush Neutral → Outperform
2023-06-26 Fortgesetzt Oppenheimer Outperform
2023-01-12 Herabstufung Guggenheim Buy → Neutral
2023-01-03 Herabstufung Wells Fargo Overweight → Equal Weight
2022-09-09 Eingeleitet Barclays Overweight
2022-06-21 Eingeleitet Jefferies Hold
2022-05-09 Herabstufung Wedbush Outperform → Neutral
2022-04-28 Eingeleitet Credit Suisse Outperform
2022-04-06 Eingeleitet Morgan Stanley Equal-Weight
2022-02-11 Fortgesetzt BMO Capital Markets Outperform
2022-02-10 Eingeleitet Wells Fargo Overweight
2022-01-19 Eingeleitet Goldman Buy
2021-12-07 Eingeleitet Cowen Outperform
2021-10-14 Eingeleitet SVB Leerink Outperform
2021-09-30 Eingeleitet Stifel Buy
2021-09-09 Eingeleitet BofA Securities Buy
2021-05-21 Eingeleitet UBS Buy
2021-04-21 Eingeleitet Truist Buy
2021-03-31 Eingeleitet BMO Capital Markets Outperform
2020-12-14 Hochstufung Oppenheimer Perform → Outperform
2020-06-01 Hochstufung Citigroup Neutral → Buy
2020-05-12 Eingeleitet Oppenheimer Perform
2019-12-19 Eingeleitet H.C. Wainwright Buy
2019-11-25 Eingeleitet Guggenheim Buy
2019-10-24 Hochstufung Goldman Neutral → Buy
2019-09-25 Eingeleitet Wedbush Outperform
2019-09-12 Eingeleitet BMO Capital Markets Outperform
2019-08-06 Eingeleitet Cantor Fitzgerald Overweight
2019-06-05 Herabstufung Citigroup Buy → Neutral
2019-04-12 Eingeleitet Evercore ISI Outperform
2018-10-22 Eingeleitet Citigroup Buy
2018-10-22 Eingeleitet Goldman Neutral
2018-10-22 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Arvinas Inc Aktie (ARVN) Neueste Nachrichten

pulisher
08:20 AM

Long Term Trading Analysis for (ARVN) - Stock Traders Daily

08:20 AM
pulisher
Dec 21, 2024

Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by State Street Corp - MarketBeat

Dec 21, 2024
pulisher
Dec 19, 2024

Arvinas (NASDAQ:ARVN) Trading Down 6.2%Time to Sell? - MarketBeat

Dec 19, 2024
pulisher
Dec 18, 2024

Arvinas (NASDAQ:ARVN) Sets New 12-Month LowWhat's Next? - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

New Haven-based Arvinas to expand Science Park footprint; renews leases - Hartford Business Journal

Dec 18, 2024
pulisher
Dec 18, 2024

New Haven-based Arvinas to expand Science Park footprint; extends leases - Hartford Business Journal

Dec 18, 2024
pulisher
Dec 18, 2024

Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results By Investing.com - Investing.com Australia

Dec 18, 2024
pulisher
Dec 18, 2024

Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results - Investing.com

Dec 18, 2024
pulisher
Dec 17, 2024

Metastatic Prostate Cancer Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Merck Sharp, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis - Barchart

Dec 17, 2024
pulisher
Dec 17, 2024

Arvinas secures expanded New Haven premises until 2029 By Investing.com - Investing.com South Africa

Dec 17, 2024
pulisher
Dec 16, 2024

Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Increases By 5.6% - MarketBeat

Dec 16, 2024
pulisher
Dec 13, 2024

Arvinas stock touches 52-week low at $21.17 amid market challenges - Investing.com Canada

Dec 13, 2024
pulisher
Dec 12, 2024

(ARVN) Trading Advice - Stock Traders Daily

Dec 12, 2024
pulisher
Dec 12, 2024

Arvinas's SWOT analysis: protein degrader's stock faces pivotal trial By Investing.com - Investing.com Nigeria

Dec 12, 2024
pulisher
Dec 12, 2024

BNP Paribas Financial Markets Lowers Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

Arvinas's SWOT analysis: protein degrader's stock faces pivotal trial - Investing.com India

Dec 12, 2024
pulisher
Dec 11, 2024

Arvinas, Pfizer’s vepdegestrant shows promise in ER+/HER2- breast cancer trial - World Pharmaceutical Frontiers

Dec 11, 2024
pulisher
Dec 11, 2024

Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

Demystifying Arvinas: Insights From 5 Analyst Reviews - Benzinga

Dec 11, 2024
pulisher
Dec 11, 2024

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial - Yahoo! Voices

Dec 11, 2024
pulisher
Dec 10, 2024

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients - Yahoo Finance

Dec 10, 2024
pulisher
Dec 10, 2024

Arvinas and Pfizer Report Promising Cancer Study Results - TipRanks

Dec 10, 2024
pulisher
Dec 10, 2024

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium - The Manila Times

Dec 10, 2024
pulisher
Dec 10, 2024

Arvinas And Pfizer Announce Initial Phase 1B Data From The Tactive-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium - XM

Dec 10, 2024
pulisher
Dec 10, 2024

Arvinas and Pfizer Announce Initial Phase 1b Data from the - GlobeNewswire

Dec 10, 2024
pulisher
Dec 10, 2024

Arvinas & Pfizer's Breast Cancer Drug Shows Promising 62.5% Clinical Benefit Rate in Phase 1b Trial - StockTitan

Dec 10, 2024
pulisher
Dec 10, 2024

BTIG Research Initiates Coverage on Arvinas (NASDAQ:ARVN) - MarketBeat

Dec 10, 2024
pulisher
Dec 09, 2024

Verition Fund Management LLC Sells 52,720 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Dec 09, 2024
pulisher
Dec 07, 2024

Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by Fmr LLC - MarketBeat

Dec 07, 2024
pulisher
Dec 05, 2024

Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by RTW Investments LP - MarketBeat

Dec 05, 2024
pulisher
Dec 04, 2024

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey

Dec 04, 2024
pulisher
Dec 04, 2024

Parkman Healthcare Partners LLC Sells 28,978 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Dec 04, 2024
pulisher
Dec 03, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire

Dec 03, 2024
pulisher
Dec 02, 2024

405,576 Shares in Arvinas, Inc. (NASDAQ:ARVN) Purchased by Baker BROS. Advisors LP - MarketBeat

Dec 02, 2024
pulisher
Dec 02, 2024

Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 02, 2024
pulisher
Dec 02, 2024

(ARVN) Investment Report - Stock Traders Daily

Dec 02, 2024
pulisher
Dec 01, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect - AccessWire

Dec 01, 2024
pulisher
Dec 01, 2024

Wasatch Advisors LP Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Braidwell LP Boosts Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Nov 30, 2024
pulisher
Nov 29, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect - AccessWire

Nov 29, 2024
pulisher
Nov 28, 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation - AccessWire

Nov 28, 2024
pulisher
Nov 28, 2024

Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN) - Simply Wall St

Nov 28, 2024
pulisher
Nov 27, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation - AccessWire

Nov 27, 2024
pulisher
Nov 27, 2024

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire

Nov 27, 2024
pulisher
Nov 27, 2024

Arvinas, Inc. (NASDAQ:ARVN) Stock Holdings Lessened by Victory Capital Management Inc. - Defense World

Nov 27, 2024
pulisher
Nov 27, 2024

Arvinas to Present at Piper Sandler Healthcare Conference; Leadership to Share Updates | ARVN Stock News - StockTitan

Nov 27, 2024
pulisher
Nov 26, 2024

BMO keeps Outperform rating on Arvinas shares, excited about vepdegestrant's progress - Investing.com

Nov 26, 2024
pulisher
Nov 26, 2024

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire

Nov 26, 2024

Finanzdaten der Arvinas Inc-Aktie (ARVN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$69.84
price up icon 1.45%
$18.67
price up icon 4.48%
$39.59
price up icon 0.51%
$363.65
price up icon 1.13%
$177.70
price up icon 0.68%
$113.51
price up icon 0.38%
Kapitalisierung:     |  Volumen (24h):